Evidence map›Paper›PMID 36049486›Full record

ArticleThe Lancet. Infectious diseases2022

The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis.

Radha Rajasingham, Nelesh P Govender, Alexander Jordan, Angela Loyse, Amir Shroufi, David W Denning, David B Meya, Tom M Chiller, David R Boulware

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in The Lancet. Infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 409 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
409citing papers in PubMed, 1 pooled it
81.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

409 citing papers in PubMed, 1 synthesis or guideline pooled it, 566 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Molecular types, clinical profile, and exploratory virulence-associated phenotypes of clinical Cryptococcus isolates from Amazonas, Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Clinical Impact and Cost-Effectiveness of Improving Access to Cryptococcal Meningitis Diagnostics and Treatment in Malawi.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

349 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 5 countries.

Radha RajasinghamDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA. Electronic address: radha@umn.edu.
Nelesh P GovenderNational Institute for Communicable Diseases, National Health Laboratory Service and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Alexander JordanCenters for Disease Control and Prevention (CDC), Atlanta, GA, USA.
Angela LoyseCentre for Global Health, Institute for Infection and Immunity, St George's University of London, London, UK.
Amir ShroufiCDC Foundation, Atlanta, GA, USA.
David W DenningFaculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK; Global Action Fund for Fungal Infections, Geneva, Switzerland.
David B MeyaDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA; Infectious Diseases Institute, Makerere University, Kampala, Uganda.
Tom M ChillerCenters for Disease Control and Prevention (CDC), Atlanta, GA, USA.
David R BoulwareDivision of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
University of Minnesota · USCenters for Disease Control and Prevention · USCDC Foundation · USGlobal Fund to Fight AIDS, Tuberculosis and Malaria · CHSt George's, University of London · GBUniversity of the Witwatersrand · ZA

Funding

Operational Research for Cryptococcal Antigen Screening (ORCAS) of HIV PatientsU01AI125003 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R, MEYA, DAVID BISAGAYA · 2016 to 2020
$3.4M
Phased Implementation of a Public Health Programme: Cryptococcal Screening and Treatment in South AfricaR01AI118511 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R, GOVENDER, NELESH PREMAPRAGASAN · 2016 to 2020
$2.9M
Evaluation of CRAG screening with enhanced antifungal therapy for asymptomatic CRAG-positive personsK23AI138851 · NIAID · UNIVERSITY OF MINNESOTA · PI RAJASINGHAM, RADHA · 2018 to 2022
$954k
NIAID NIH HHS K23 AI138851NIAID NIH HHS R01 AI118511NIAID NIH HHS U01 AI125003
6 · The paper itself

Abstract

backgroundCryptococcal meningitis is the most common cause of meningitis in adults living with HIV in sub-Saharan Africa. The estimates of national, regional, and global burden of cryptococcal meningitis are essential to guide prevention strategies and determine needs for diagnostic tests and treatments. We present a 2020 estimate of the global burden of HIV-associated cryptococcal infection (antigenaemia), cryptococcal meningitis, and cryptococcal-associated deaths.

methodsWe defined advanced HIV disease as adults with a CD4 count of less than 200 cells/μL, as this group is at highest risk for cryptococcosis. We used UNAIDS estimates (2019-20) and population-based HIV impact assessment surveys (2016-18) to estimate the number of adults with CD4 counts of less than 200 cells/μL at risk for cryptococcosis, by country and region. Secondly, we summarised cryptococcal antigenaemia prevalence in those with a CD4 count of less than 200 cells/μL by reviewing published literature. Thereafter, we calculated the number of cryptococcal antigen (CrAg)-positive people in each country and region by multiplying the number with advanced HIV disease at risk for cryptococcal infection by the cryptococcal antigenaemia prevalence of the respective country or region. We estimated progression from cryptococcal antigenaemia to meningitis or death based on estimates from the published literature.

findingsWe estimated that there were 4·3 million (IQR 3·0-4·8) adults with HIV and CD4 counts of less than 200 cells/μL globally in 2020. We calculated a mean global cryptococcal antigenaemia prevalence of 4·4% (95% CI 1·6-7·4) among HIV-positive people with CD4 counts of less than 200 cells/μL, corresponding to 179 000 cases (IQR 133 000-219 000) of cryptococcal antigenaemia globally in 2020. Annually, we estimated that there are 152 000 cases (111 000-185 000) of cryptococcal meningitis, resulting in 112 000 cryptococcal-related deaths (79 000-134 000). Globally, cryptococcal disease accounts for 19% (13-24) of AIDS-related mortality.

interpretationDespite a reduction in the estimated absolute global burden of HIV-associated cryptococcal meningitis compared with 2014, likely to be due to antiretroviral therapy expansion, cryptococcal disease still accounts for 19% of AIDS-related deaths, similar to 2014 estimates. To end cryptococcal meningitis deaths by 2030, cryptococcal diagnostics, meningitis treatments, and implementation of preventive screening are urgently needed.

fundingNone.

Indexed as

Acquired Immunodeficiency SyndromeAIDS-Related Opportunistic InfectionsCryptococcosisCryptococcusHIV InfectionsMeningitis, CryptococcalAdultAntigens, FungalCD4 Lymphocyte CountHumansAntigens, Fungal

Identifiers

PMID36049486
PMCPMC9701154
OpenAlexW4293509742

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.